Biaryl substituted heterocycle inhibitors of LTA4H for...

Organic compounds -- part of the class 532-570 series – Organic compounds – Heterocyclic carbon compounds containing a hetero ring...

Reexamination Certificate

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

C514S428000

Reexamination Certificate

active

07402684

ABSTRACT:
The present invention relates to a chemical genus of biaryl substituted heterocycle inhibitors of LTA4H (leukotriene A4 hydrolase) useful for the treatment and prevention and prophylaxis of inflammatory diseases and disorders. The compounds have general formula Ψ:An example is

REFERENCES:
patent: 2005/0043379 (2005-02-01), Axe et al.
patent: EP 0895989 (1999-02-01), None
patent: WO 03/075921 (2004-02-01), None
patent: WO 2004/016609 (2004-02-01), None
Penning, Thomas, “Inhibitors of Leukotriene A4 (LTA4) Hydrolase as Potential Anti-Inflammatory Agents,” Current Pharmaceutical Design, 2001, pp. 163-179.
Penning, Thomas et al., “Synthesis of Imadazophyridines and Purines as Potent Inhibitors of Leukotriene A4 Hydrolase,” Bioorganic & Medicinal Chemistry Letters 13, 2003, pp. 1137-1139.
PCT Search Report based International application No. PCT/2006/024393.

LandOfFree

Say what you really think

Search LandOfFree.com for the USA inventors and patents. Rate them and share your experience with other people.

Rating

Biaryl substituted heterocycle inhibitors of LTA4H for... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Biaryl substituted heterocycle inhibitors of LTA4H for..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Biaryl substituted heterocycle inhibitors of LTA4H for... will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFUS-PAI-O-2807613

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.